Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 4/2017

01-04-2017 | Original Paper

A Hazard Analysis of Risk Factors of Mortality in Individuals Who Inject Drugs in Denver CO

Authors: Jonathan M. Davis, Katie Suleta, Karen F. Corsi, Robert E. Booth

Published in: AIDS and Behavior | Issue 4/2017

Login to get access

Abstract

Despite multiple risk factors for mortality among People Who Inject Drugs (PWID), more research is warranted that examines sub-populations within PWID. Mortality data from PWID participating in longitudinal HIV prevention research in Denver were obtained from The Colorado Department of Public Health and Environment. Risk factors for both all-cause and acute-toxicity related mortality were analyzed using Cox proportional hazards regression. Two-thousand seven individuals were interviewed at baseline. Eighty-six individuals died during the time frame of the study, 58 of which were due to acute-toxicity. Disabled (HR = 3.3, p < 0.001), gay/lesbian-identified (HR = 2.6, p = 0.03), white race/ethnicity (HR = 2.4, p = 0.003), and use of a shared cooker (HR = 2.1, p = 0.01) were important adjusted risk factors. These suggest that drug and HIV interventions should utilize techniques that can address the needs of marginalized populations in addition to HIV drug risk behaviors.
Literature
1.
Darke S, Zador D. Fatal heroin “overdose”: a review. Addict Abingdon Engl. 1996;91(12):1765–72.CrossRef
2.
Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addict Abingdon Engl. 1994;89(10):1299–308.CrossRef
3.
Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health. 1991;81(10):1307–10.CrossRefPubMedPubMedCentral
4.
Vaillant GE. A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatr. 1973;29(2):237–41.CrossRefPubMed
5.
Hulse GK, English DR, Milne E, Holman CD. The quantification of mortality resulting from the regular use of illicit opiates. Addict Abingdon Engl. 1999;94(2):221–9.CrossRef
6.
Frischer M, Bloor M, Goldberg D, Clark J, Green S, McKeganey N. Mortality among injecting drug users: a critical reappraisal. J Epidemiol Community Health. 1993;47(1):59–63.CrossRefPubMedPubMedCentral
7.
Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.CrossRefPubMedPubMedCentral
8.
Artenie AA, Bruneau J, Zang G, Lespérance F, Renaud J, Tremblay J, et al. Associations of substance use patterns with attempted suicide among persons who inject drugs: can distinct use patterns play a role? Drug Alcohol Depend. 2015;1(147):208–14.CrossRef
9.
Marshall BDL, Galea S, Wood E, Kerr T. Injection methamphetamine use is associated with an increased risk of attempted suicide: a prospective cohort study. Drug Alcohol Depend. 2011;119(1–2):134–7.CrossRefPubMedPubMedCentral
10.
11.
Selwyn PA, Hartel D, Wasserman W, Drucker E. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health. 1989;79(10):1358–62.CrossRefPubMedPubMedCentral
12.
Gjersing L, Bretteville-Jensen AL. Gender differences in mortality and risk factors in a 13-year cohort study of street-recruited injecting drug users. BMC Public Health. 2014;14:440.CrossRefPubMedPubMedCentral
13.
Zivanovic R, Milloy MJ, Hayashi K, Dong H, Sutherland C, Kerr T, et al. Impact of unstable housing on all-cause mortality among persons who inject drugs. BMC Public Health. 2015;15:106.CrossRefPubMedPubMedCentral
14.
Borriello R, Carfora A, Cassandro P, Petrella R. A five years study on drug-related deaths in Campania (Italy). Ann DellIstituto Super Sanità. 2014;50(4):328–33.
15.
Grant BF, Harford TC. Concurrent and simultaneous use of alcohol with cocaine: results of national survey. Drug Alcohol Depend. 1990;25(1):97–104.CrossRefPubMed
16.
O’Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health. 2001;91(6):984–7.CrossRefPubMedPubMedCentral
17.
Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addict Abingdon Engl. 2011;106(1):32–51.CrossRef
18.
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774–80.CrossRefPubMedPubMedCentral
19.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.CrossRefPubMedPubMedCentral
20.
Binswanger IA, Blatchford PJ, Lindsay RG, Stern MF. Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. Drug Alcohol Depend. 2011;117(1):1–6.CrossRefPubMed
21.
Mathers BM, Degenhardt L. Examining non-AIDS mortality among people who inject drugs. AIDS Lond Engl. 2014;28(Suppl 4):S435–44.CrossRef
22.
Islam MM, Topp L, Day CA, Dawson A, Conigrave KM. The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Int J Drug Policy. 2012;23(2):94–102.CrossRefPubMed
23.
Booth RE, Kwiatkowski C, Iguchi MY, Pinto F, John D. Facilitating treatment entry among out-of-treatment injection drug users. Public Health Rep. 1998;113(1):116–28.PubMedPubMedCentral
24.
Booth RE, Corsi KF, Mikulich SK. Improving entry to methadone maintenance among out-of-treatment injection drug users. J Subst Abuse Treat. 2003;24(4):305–11.CrossRefPubMed
25.
Evans E, Kelleghan A, Li L, Min J, Huang D, Urada D, et al. Gender differences in mortality among treated opioid dependent patients. Drug Alcohol Depend. 2015;1(155):228–35.CrossRef
26.
Forman-Hoffman VL, Ault KL, Anderson WL, Weiner JM, Stevens A, Campbell VA, et al. Disability status, mortality, and leading causes of death in the United States community population. Med Care. 2015;53(4):346–54.PubMedPubMedCentral
27.
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70.CrossRefPubMed
28.
Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.CrossRefPubMedPubMedCentral
29.
Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manag. 2004;28(2):176–88.CrossRef
30.
Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. “Every ‘never’ I ever said came true”: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25(2):257–66.CrossRefPubMed
31.
32.
Hatzenbuehler ML, Bellatorre A, Lee Y, Finch BK, Muennig P, Fiscella K. Structural stigma and all-cause mortality in sexual minority populations. Soc Sci Med. 2014;103:33–41.CrossRefPubMed
33.
34.
Nambiar D, Weir A, Aspinall EJ, Stoové M, Hutchinson S, Dietze P, et al. Mortality and cause of death in a cohort of people who had ever injected drugs in Glasgow: 1982–2012. Drug Alcohol Depend. 2015;1(147):215–21.CrossRef
35.
Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health. 2006;16(2):198–202.CrossRefPubMed
36.
Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011;113(2–3):88–95.CrossRefPubMed
37.
Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet Lond Engl. 2014;384(9937):45–52.CrossRef
38.
Armour BS, Campbell VA, Crews JE, Malarcher A, Maurice E, Richard RA. State-level prevalence of cigarette smoking and treatment advice, by disability status, United States, 2004. Prev Chronic Dis. 2007;4(4):A86.PubMedPubMedCentral
39.
Carroll DD, Courtney-Long EA, Stevens AC, Sloan ML, Lullo C, Visser SN, et al. Vital signs: disability and physical activity–United States, 2009–2012. MMWR Morb Mortal Wkly Rep. 2014;63(18):407–13.PubMed
40.
41.
Dilley JA, Simmons KW, Boysun MJ, Pizacani BA, Stark MJ. Demonstrating the importance and feasibility of including sexual orientation in public health surveys: health disparities in the Pacific Northwest. Am J Public Health. 2010;100(3):460–7.CrossRefPubMedPubMedCentral
42.
Garland-Forshee RY, Fiala SC, Ngo DL, Moseley K. Sexual orientation and sex differences in adult chronic conditions, health risk factors, and protective health practices, Oregon, 2005–2008. Prev Chronic Dis. 2014;11:E136.CrossRefPubMedPubMedCentral
43.
Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–1998. Addict Abingdon Engl. 2003;98(6):739–47.CrossRef
44.
Leece P, Cavacuiti C, Macdonald EM, Gomes T, Kahan M, Srivastava A, et al. Predictors of opioid-related death during methadone therapy. J Subst Abuse Treat. 2015;57:30–5.CrossRefPubMed
45.
Darke S, Williamson A, Ross J, Teesson M, Lynskey M. Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend. 2004;74(1):77–83.CrossRefPubMed
46.
Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Psychiatric correlates of injection risk behavior among young people who inject drugs. Psychol Addict Behav J Soc Psychol Addict Behav. 2014;28(4):1089–95.CrossRef
47.
Fossati A, Barratt ES, Carretta I, Leonardi B, Grazioli F, Maffei C. Predicting borderline and antisocial personality disorder features in nonclinical subjects using measures of impulsivity and aggressiveness. Psychiatry Res. 2004;125(2):161–70.CrossRefPubMed
48.
Teese R, Bradley G. Predicting recklessness in emerging adults: a test of a psychosocial model. J Soc Psychol. 2008;148(1):105–26.CrossRefPubMed
49.
50.
Buster MCA, van Brussel GHA, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addict Abingdon Engl. 2002;97(8):993–1001.CrossRef
51.
Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177–96.CrossRefPubMed
52.
Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat. 2011;41(3):252–60.CrossRefPubMed
53.
Harlow KC. Patterns of rates of mortality from narcotics and cocaine overdose in Texas, 1976–1987. Public Health Rep. 1990;105(5):455–62.PubMedPubMedCentral
54.
Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. Addict Abingdon Engl. 2008;103(1):126–36.CrossRef
55.
Horyniak D, Dietze P, Degenhardt L, Higgs P, McIlwraith F, Alati R, et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug Alcohol Depend. 2013;132(3):541–6.CrossRefPubMed
56.
Roth AM, Armenta RA, Wagner KD, Roesch SC, Bluthenthal RN, Cuevas-Mota J, et al. Patterns of drug use, risky behavior, and health status among persons who inject drugs living in San Diego, California: a latent class analysis. Subst Use Misuse. 2015;50(2):205–14.CrossRefPubMed
57.
Del Boca FKN, Jane A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction. 2000;10(95):S347–60.CrossRef
58.
Harrison L. The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA Res Monogr. 1997;167:17–36.PubMed
Metadata
Title
A Hazard Analysis of Risk Factors of Mortality in Individuals Who Inject Drugs in Denver CO
Authors
Jonathan M. Davis
Katie Suleta
Karen F. Corsi
Robert E. Booth
Publication date
01-04-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1660-y

Other articles of this Issue 4/2017

AIDS and Behavior 4/2017 Go to the issue

Brief Report

Correlates of Double Risk of HIV Acquisition and Transmission Among Women who Inject Drugs in St. Petersburg, Russia

Erratum

Erratum to: Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV

Original Article

Gender, Transience, Network Partnerships and Risky Sexual Practices Among Young Persons who Inject Drugs

Original Paper

The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis

Original Paper

Erectile Dysfunction Medication Prescription and Condomless Intercourse in HIV-Infected Men Who have Sex with Men in the United States

Original Paper

Social Network Influence on HIV Testing Among Urban Men in Tanzania
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits